Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma
Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated with clinical outcomes for ICIs in several tumor types. We aim to assess the value of the LIPI i...
| Autores: | , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Pompeu Fabra |
| Repositorio: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:repositori.upf.edu:10230/59948 |
| Acceso en línea: | http://hdl.handle.net/10230/59948 http://dx.doi.org/10.3390/cancers15041066 |
| Access Level: | acceso abierto |
| Palabra clave: | LIPI score Biomarker Immune checkpoint inhibitors Prognosis Urothelial cancer |
| id |
ES_1d36de57fb5b1d9c78f92d00a43b4c1b |
|---|---|
| oai_identifier_str |
oai:repositori.upf.edu:10230/59948 |
| network_acronym_str |
ES |
| network_name_str |
España |
| spelling |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma Parent, Pauline Auclin, Edouard Patrikidou, Anna Mezquita, Laura Martínez Chanzá, Nieves Dumont, Clement Rodriguez-Vida, Alejo Llacer, Casilda Lozano, Rebeca Ratta, Raffaele Merseburger, Axel S. Sternberg, Cora N. Baciarello, Giulia Colomba, Emeline Fuerea, Alina Besse, Benjamin Loriot, Yohann Lavaud, Pernelle LIPI score Biomarker Immune checkpoint inhibitors Prognosis Urothelial cancer Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated with clinical outcomes for ICIs in several tumor types. We aim to assess the value of the LIPI in patients with mUC treated with ICIs. A retrospective ICI cohort and a validation cohort (SAUL cohort) included, respectively, patients with mUC treated with ICI in 8 European centers (any line) and patients treated with atezolizumab in a second or further line. A chemotherapy-only cohort was also analyzed. The LIPI score was based on 2 factors, derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) > 3 and lactate dehydrogenase > upper limit of normal, and defined 3 prognostic groups. The association of LIPI with progression-free survival (PFS) and overall survival (OS) was assessed. In the ICI and SAUL cohorts, 137 and 541 patients were respectively analyzed. In the ICI cohort, mPFS and mOS were 3.6 mo (95% CI; 2.6-6.0) and 13.8 mo (95% CI; 11.5-23.2) whereas in the SAUL cohort the mPFS and mOS were 2.2 mo (95% CI; 2.1-2.3) and 8.7 mo (95% CI; 7.8-9.9) respectively. The LIPI classified the population of these cohorts in good (56%; 52%), intermediate (35%; 36%) and poor (9%; 12%) prognostic groups (values for the ICI and SAUL cohorts respectively). Poor LIPI was associated with a poorer OS in both cohorts: hazard ratio (HR) for the ICI cohort = 2.69 (95% CI; 1.24-5.84, p = 0.035); HR = 2. 89 for the SAUL cohort (CI 95%: 1.93-4.32, p < 0.0001). Similar results were found in the chemo cohort. The LIPI score allows to identify different subgroups in patients with good prognostis according to the Bellmunt score criteria, with a subset of patients with poorer outcomes having an mOS of 3.7 mo compared to the good and intermediate LIPI subgroups with mOS of 17.9 and 7.4 mo, respectively. The LIPI score was associated with survival in mUC patients treated by ICIs. Future prospective studies will be required to test the combination of Bellmunt score and the LIPI score as a more accurate prognosis tool. MDPI http://hdl.handle.net/10230/59948 http://dx.doi.org/10.3390/cancers15041066 |
| title |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma |
| spellingShingle |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma Parent, Pauline LIPI score Biomarker Immune checkpoint inhibitors Prognosis Urothelial cancer |
| title_short |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma |
| title_full |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma |
| title_fullStr |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma |
| title_full_unstemmed |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma |
| title_sort |
Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma |
| author |
Parent, Pauline |
| author_facet |
Parent, Pauline Auclin, Edouard Patrikidou, Anna Mezquita, Laura Martínez Chanzá, Nieves Dumont, Clement Rodriguez-Vida, Alejo Llacer, Casilda Lozano, Rebeca Ratta, Raffaele Merseburger, Axel S. Sternberg, Cora N. Baciarello, Giulia Colomba, Emeline Fuerea, Alina Besse, Benjamin Loriot, Yohann Lavaud, Pernelle |
| author_role |
author |
| author2 |
Auclin, Edouard Patrikidou, Anna Mezquita, Laura Martínez Chanzá, Nieves Dumont, Clement Rodriguez-Vida, Alejo Llacer, Casilda Lozano, Rebeca Ratta, Raffaele Merseburger, Axel S. Sternberg, Cora N. Baciarello, Giulia Colomba, Emeline Fuerea, Alina Besse, Benjamin Loriot, Yohann Lavaud, Pernelle |
| author2_role |
author author author author author author author author author author author author author author author author author |
| topic |
LIPI score Biomarker Immune checkpoint inhibitors Prognosis Urothelial cancer |
| topic_facet |
LIPI score Biomarker Immune checkpoint inhibitors Prognosis Urothelial cancer |
| description |
Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated with clinical outcomes for ICIs in several tumor types. We aim to assess the value of the LIPI in patients with mUC treated with ICIs. A retrospective ICI cohort and a validation cohort (SAUL cohort) included, respectively, patients with mUC treated with ICI in 8 European centers (any line) and patients treated with atezolizumab in a second or further line. A chemotherapy-only cohort was also analyzed. The LIPI score was based on 2 factors, derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) > 3 and lactate dehydrogenase > upper limit of normal, and defined 3 prognostic groups. The association of LIPI with progression-free survival (PFS) and overall survival (OS) was assessed. In the ICI and SAUL cohorts, 137 and 541 patients were respectively analyzed. In the ICI cohort, mPFS and mOS were 3.6 mo (95% CI; 2.6-6.0) and 13.8 mo (95% CI; 11.5-23.2) whereas in the SAUL cohort the mPFS and mOS were 2.2 mo (95% CI; 2.1-2.3) and 8.7 mo (95% CI; 7.8-9.9) respectively. The LIPI classified the population of these cohorts in good (56%; 52%), intermediate (35%; 36%) and poor (9%; 12%) prognostic groups (values for the ICI and SAUL cohorts respectively). Poor LIPI was associated with a poorer OS in both cohorts: hazard ratio (HR) for the ICI cohort = 2.69 (95% CI; 1.24-5.84, p = 0.035); HR = 2. 89 for the SAUL cohort (CI 95%: 1.93-4.32, p < 0.0001). Similar results were found in the chemo cohort. The LIPI score allows to identify different subgroups in patients with good prognostis according to the Bellmunt score criteria, with a subset of patients with poorer outcomes having an mOS of 3.7 mo compared to the good and intermediate LIPI subgroups with mOS of 17.9 and 7.4 mo, respectively. The LIPI score was associated with survival in mUC patients treated by ICIs. Future prospective studies will be required to test the combination of Bellmunt score and the LIPI score as a more accurate prognosis tool. |
| publishDate |
2023 |
| format |
article |
| status_str |
publishedVersion |
| url |
http://hdl.handle.net/10230/59948 http://dx.doi.org/10.3390/cancers15041066 |
| eu_rights_str_mv |
openAccess |
| publisher |
MDPI |
| institution |
Universitat Pompeu Fabra |
| collection |
Repositorio Digital de la UPF |
| reponame_str |
Repositorio Digital de la UPF |
| instname_str |
Universitat Pompeu Fabra |
| _version_ |
1878432169943105537 |
| publishDateSort |
2023 |
| author_browse |
Auclin, Edouard Baciarello, Giulia Besse, Benjamin Colomba, Emeline Dumont, Clement Fuerea, Alina Lavaud, Pernelle Llacer, Casilda Loriot, Yohann Lozano, Rebeca Martínez Chanzá, Nieves Merseburger, Axel S. Mezquita, Laura Parent, Pauline Patrikidou, Anna Ratta, Raffaele Rodriguez-Vida, Alejo Sternberg, Cora N. |
| publisherStr |
MDPI |
| score |
6,9303427 |